Philip H. Kim

1.9k total citations
30 papers, 969 citations indexed

About

Philip H. Kim is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Philip H. Kim has authored 30 papers receiving a total of 969 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Surgery, 12 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in Philip H. Kim's work include Bladder and Urothelial Cancer Treatments (16 papers), Urinary and Genital Oncology Studies (11 papers) and Renal cell carcinoma treatment (5 papers). Philip H. Kim is often cited by papers focused on Bladder and Urothelial Cancer Treatments (16 papers), Urinary and Genital Oncology Studies (11 papers) and Renal cell carcinoma treatment (5 papers). Philip H. Kim collaborates with scholars based in United States, France and Canada. Philip H. Kim's co-authors include A. Ari Hakimi, Harry W. Herr, John P. Sfakianos, Ling Y. Chen, Paul Russo, James A. Eastham, Emily C. Zabor, Victor E. Reuter, Nikolaus Schultz and Coral L. Atoria and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Philip H. Kim

30 papers receiving 959 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philip H. Kim United States 15 475 383 281 209 207 30 969
Katsuya Aoki Japan 15 381 0.8× 162 0.4× 188 0.7× 192 0.9× 229 1.1× 52 843
Yasunobu Hashimoto Japan 20 563 1.2× 630 1.6× 283 1.0× 169 0.8× 265 1.3× 84 1.2k
Mark H. Kawachi United States 18 403 0.8× 552 1.4× 232 0.8× 178 0.9× 145 0.7× 37 1.1k
Nawar Hanna United States 15 529 1.1× 570 1.5× 271 1.0× 146 0.7× 180 0.9× 38 951
S. Rocca Rossétti Italy 12 200 0.4× 449 1.2× 186 0.7× 81 0.4× 206 1.0× 26 677
Xu-Dong Yao China 17 378 0.8× 307 0.8× 256 0.9× 180 0.9× 108 0.5× 35 827
Gianni Vittori Italy 18 357 0.8× 611 1.6× 357 1.3× 231 1.1× 143 0.7× 59 983
Laura-Maria Krabbe United States 20 615 1.3× 531 1.4× 310 1.1× 122 0.6× 185 0.9× 41 1.0k
Martijn G. Steffens Netherlands 16 205 0.4× 327 0.9× 275 1.0× 234 1.1× 132 0.6× 54 867
Vito Mancini Italy 18 240 0.5× 294 0.8× 173 0.6× 179 0.9× 140 0.7× 64 805

Countries citing papers authored by Philip H. Kim

Since Specialization
Citations

This map shows the geographic impact of Philip H. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip H. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip H. Kim more than expected).

Fields of papers citing papers by Philip H. Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip H. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip H. Kim. The network helps show where Philip H. Kim may publish in the future.

Co-authorship network of co-authors of Philip H. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Philip H. Kim. A scholar is included among the top collaborators of Philip H. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip H. Kim. Philip H. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McPherson, Victor, Brendan Reardon, Sasinya N. Scott, et al.. (2020). A phase 2 trial of buparlisib in patients with platinum‐resistant metastatic urothelial carcinoma. Cancer. 126(20). 4532–4544. 20 indexed citations
2.
Danforth, Kim N., Tiffany Luong, Ayae Yamamoto, et al.. (2019). Disparities in Stage at Diagnosis in an Equal-access Integrated Delivery System: A Retrospective Cohort Study of 7244 Patients With Bladder Cancer. Clinical Genitourinary Cancer. 18(2). e91–e102. 15 indexed citations
3.
4.
Anderson, Christopher B., Itay Sternberg, Philip H. Kim, et al.. (2015). Age is Associated with Upgrading at Confirmatory Biopsy among Men with Prostate Cancer Treated with Active Surveillance. The Journal of Urology. 194(6). 1607–1611. 14 indexed citations
5.
Rosenberg, Jonathan E., Eliezer M. Van Allen, Kent W. Mouw, et al.. (2014). Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma.. Journal of Clinical Oncology. 32(15_suppl). 4510–4510. 3 indexed citations
6.
Kim, Philip H., K. Eugene, John P. Sfakianos, et al.. (2014). Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. European Urology. 67(2). 198–201. 105 indexed citations
7.
Sfakianos, John P., Lan L. Gellert, Alexandra C. Maschino, et al.. (2014). The role of PTEN tumor suppressor pathway staining in carcinoma in situ of the bladder. Urologic Oncology Seminars and Original Investigations. 32(5). 657–662. 15 indexed citations
8.
Eugene, K., John P. Sfakianos, Hikmat Al‐Ahmadie, et al.. (2014). Branched evolution and intratumor heterogeneity of urothelial carcinoma of the bladder.. Journal of Clinical Oncology. 32(4_suppl). 293–293. 6 indexed citations
9.
10.
Hakimi, A. Ari, et al.. (2013). The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma. Canadian Urological Association Journal. 7(11-12). 687–687. 31 indexed citations
11.
Poon, Stephen A., Jonathan Silberstein, Ling Y. Chen, et al.. (2013). Trends in Partial and Radical Nephrectomy: An Analysis of Case Logs from Certifying Urologists. The Journal of Urology. 190(2). 464–469. 51 indexed citations
12.
Hakimi, A. Ari, Reza Ghavamian, Philip H. Kim, et al.. (2013). Factors That Affect Proportional Glomerular Filtration Rate After Minimally Invasive Partial Nephrectomy. Journal of Endourology. 27(11). 1371–1375. 7 indexed citations
13.
Hong, Sung Kyu, Itay Sternberg, Gal E. Keren Paz, et al.. (2013). Definitive Pathology at Radical Prostatectomy Is Commonly Favorable in Men Following Initial Active Surveillance. European Urology. 66(2). 214–219. 20 indexed citations
14.
Hakimi, A. Ari, Helena Furberg, Emily C. Zabor, et al.. (2013). An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma. JNCI Journal of the National Cancer Institute. 105(24). 1862–1870. 214 indexed citations
15.
Kim, Philip H., Laura C. Pinheiro, Coral L. Atoria, Jaspreet S. Sandhu, & Elena B. Elkin. (2012). 507 TRENDS IN THE USE OF INCONTINENCE PROCEDURES AFTER RADICAL PROSTATECTOMY: A POPULATION-BASED ANALYSIS. The Journal of Urology. 187(4S). 13 indexed citations
16.
Kim, Philip H., Laura C. Pinheiro, Coral L. Atoria, et al.. (2012). Trends in the Use of Incontinence Procedures After Radical Prostatectomy: A Population Based Analysis. The Journal of Urology. 189(2). 602–608. 87 indexed citations
17.
Kim, Philip H., Mukul Patil, Steve Kim, et al.. (2011). Early comparison of nephrectomy options in children (open, transperitoneal laparoscopic, laparo‐endoscopic single site (LESS), and robotic surgery). British Journal of Urology. 109(6). 910–915. 21 indexed citations
18.
Lee, Dennis J., Philip H. Kim, & Chester J. Koh. (2010). Current Trends in Pediatric Minimally Invasive Urologic Surgery. Korean journal of urology. 51(2). 80–80. 8 indexed citations
19.
Huang, George J., Philip H. Kim, Donald G. Skinner, & John P. Stein. (2008). Outcomes of patients with clinical CIS-only disease treated with radical cystectomy. World Journal of Urology. 27(1). 21–25. 9 indexed citations
20.
Gunn, Teresa M., Arezou Azarani, Philip H. Kim, et al.. (2002). Identification and preliminary characterization of mouse Adam33. BMC Genetics. 3(1). 2–2. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katsuya Aoki Breakdown of academic impact, for papers by Yasunobu Hashimoto Breakdown of academic impact, for papers by Mark H. Kawachi Breakdown of academic impact, for papers by Nawar Hanna Breakdown of academic impact, for papers by S. Rocca Rossétti Breakdown of academic impact, for papers by Xu-Dong Yao Breakdown of academic impact, for papers by Gianni Vittori Breakdown of academic impact, for papers by Laura-Maria Krabbe Breakdown of academic impact, for papers by Martijn G. Steffens Breakdown of academic impact, for papers by Vito Mancini
Rankless by CCL
2026